AstraZeneca in Japan bet
UK-BASED pharma giant AstraZeneca said yesterday that it has bought the part of its Japanese arm that it did not own from Sumitomo Chemical, for around 10bn yen (£60m).
The decision to take over all of the shares in AstraZeneca KK “reinforces our focus on Japan as a key growth platform,” the company said.
Meanwhile, GlaxoSmithKline has withdrawn a marketing application for a melanoma treatment yet had approval for diabetes drug Eperzan.